|
HY-10016-10mg
|
MedChemexpress LLC
|
E 2012 [CAS 870843-42-8]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-10016-100mg
|
MedChemexpress LLC
|
E 2012 [CAS 870843-42-8]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-10016-5mg
|
MedChemexpress LLC
|
E 2012 [CAS 870843-42-8]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-100181-10mg
|
MedChemexpress LLC
|
PF-04991532 [CAS 1215197-37-7]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-100181-100mg
|
MedChemexpress LLC
|
PF-04991532 [CAS 1215197-37-7]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-100181-25mg
|
MedChemexpress LLC
|
PF-04991532 [CAS 1215197-37-7]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-100181-5mg
|
MedChemexpress LLC
|
PF-04991532 [CAS 1215197-37-7]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-100181-50mg
|
MedChemexpress LLC
|
PF-04991532 [CAS 1215197-37-7]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-100208-10mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-100mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-25mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-5mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-50mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100302-1mg
|
MedChemexpress LLC
|
FR183998 free base [CAS 239440-20-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-100302-10mg
|
MedChemexpress LLC
|
FR183998 free base [CAS 239440-20-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-100302-100mg
|
MedChemexpress LLC
|
FR183998 free base [CAS 239440-20-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-100302-25mg
|
MedChemexpress LLC
|
FR183998 free base [CAS 239440-20-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-100302-5mg
|
MedChemexpress LLC
|
FR183998 free base [CAS 239440-20-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-100302-50mg
|
MedChemexpress LLC
|
FR183998 free base [CAS 239440-20-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-10037-10mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-10037-100mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-10037-5mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-10037-50mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-100371-1mg
|
MedChemexpress LLC
|
(RS)-MCPG [CAS 146669-29-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100371-10mg
|
MedChemexpress LLC
|
(RS)-MCPG [CAS 146669-29-6]
|
|
Neuroscience-Neuromodulation
|
|
